ATC Group: C10BX Lipid modifying agents in combination with other drugs

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C10BX in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C10 Lipid modifying agents
3 C10B Lipid modifying agents, combinations
4 C10BX Lipid modifying agents in combination with other drugs

Group C10BX contents

Code Title
C10BX01 Simvastatin and acetylsalicylic acid
C10BX02 Pravastatin and acetylsalicylic acid
C10BX03 Atorvastatin and amlodipine
C10BX04
C10BX05
C10BX06
C10BX07
C10BX08
C10BX09
C10BX10
C10BX11
C10BX12
C10BX13
C10BX14
C10BX15
C10BX16
C10BX17
C10BX18
C10BX19
C10BX20
C10BX21

Active ingredients in C10BX

Active Ingredient Description
Atorvastatin and Amlodipine

Combination of two drugs, a dihydropyridine calcium channel blocker, amlodipine, and an HMG-CoA reductase inhibitor, atorvastatin. The amlodipine component of CADUET inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The atorvastatin component of CADUET is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.

Atorvastatin and Perindopril

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE). Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity and reduced secretion of aldosterone. Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein-kinin systems (and thus also activation of the prostaglandin system).

Atorvastatin, Amlodipine and Perindopril

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II. Inhibition of ACE results in a reduction of angiotensin II in the plasma, which leads to increased plasma renin activity (by inhibition of the negative feedback of renin release) and reduced secretion of aldosterone. Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.

Related product monographs

Title Information Source Document Type  
CADUET Film-coated tablet Marketing Authorisation Holder MPI, US: SPL/PLR
LIPERCOSYL Capsules, hard Health Products Regulatory Authority (IE) MPI, EU: SmPC
TRIVERAM Film-coated tablet Health Sciences Authority (SG) MPI, EU: SmPC